KRAS and neoplasm: We identified that up to 9.1% of the isolated CHCs harbored an oncogenic KRAS allele while the leukocyte fraction only expressed wild type KRAS (Fig. 1D), indicating that CHCs derive from the primary tumor and retain key genomic drivers of cancer progression.